Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00573508 · ClinicalTrials.gov registry record · Phase 4
Study of VESIcare® In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life
A Phase 4 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 4
- Development phase
- 768
- Enrollment target
NCT00573508: Completed Phase 4 study, sponsored by Astellas Pharma.
NCT00573508 is a Phase 4 study that has completed, run by Astellas Pharma. The registered enrollment target is 768 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (48% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00573508, a Phase 4 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 768 participants
- Enrollment target
Study Summary
Evaluate the effect of VESIcare® on symptom bother for subjects with OAB
Primary Outcome
The OAB-q is used to assess how much a patient is bothered by OAB symptoms \& the impact of these symptoms on the patient's Health Related Quality of Life(HRQL). It is a patient administered tool comprised of 33 items, where the first 8 define symptom bother with raw score being converted to a scale of 0 to 100. Higher score values are indicative of greater symptom severity or bother, and a lower score in change from baseline indicates improvement. End of Treatment results include patients who
Interventions
- DRUG Placebo
- DRUG Solifenacin Succinate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 768 participants |
| Start Date | 2007-08 |
| Est. Completion | 2008-07 |
| Phase | Phase 4 |
What the finished NCT00573508 record still lists
NCT00573508 is an interventional study that assigns participants to a tested intervention. The registered 768 participants enrollment target is mid-sized for trials with a published cap, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (48% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00573508 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00573508 about?
NCT00573508 is a clinical study titled "Study of VESIcare® In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life". Evaluate the effect of VESIcare® on symptom bother for subjects with OAB
What is the current status of trial NCT00573508?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 768 participants. The study started on 2007-08. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00573508?
The interventions under investigation include: Placebo (DRUG), Solifenacin Succinate (DRUG).
Who is sponsoring clinical trial NCT00573508?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00573508's enrollment target sits among peer trials
768 105th of 2000 higher than 1,896 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05119556 · 768 participants · NA
Video Telehealth Pulmonary Rehabilitation to Reduce Hospital Readmission in Chronic Obstructive Pulmonary Disease
- NCT05404750 · 768 participants
Harm Reduction in HIV Primary Care for PLWH Who Use Drugs
- NCT05660525 · 768 participants · NA
Leveraging Community Pharmacists to Optimize Smoking Cessation Services for Rural Smokers in Appalachia
- NCT06324357 · 768 participants · Phase 1
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia